Project Grant R43DA060033
Award Date
5/15/24
Completion Date
4/30/25
Dollars Obligated
$480K
Federal Agency
National Institute on Drug Abuse
Awardee
Cibots Inc. (W6FWBNH967D5)
Federal Grant Program
93.279
Assistance Type
Project Grant
Place of Performance
La Costa, CA 92011, USA
Similar Awards
The National Institute on Drug Abuse (NIDA) awarded a $2,925,374 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to Clear Scientific, LLC to develop a novel reversal agent for treating overdoses from the combination of fentanyl and xylazine. The funding will support a 2-year research project with the goal of identifying a lead candidate compound that can simultaneously restore respiration and reverse sedation caused by these co-ingested substances. Key...
This Project Grant from the National Institutes of Health National Institute on Drug Abuse, under the Drug Abuse and Addiction Research Programs (CFDA 93.279), provides $889,713 to The Ohio State University from April 2021 through March 2023. The funding supports research to develop dual-cavity baskets assembled into nanoparticles as nano-antidotes for overdose with fentanyl and its derivatives. Specifically, the awardee will functionalize dual-cavity baskets with biocompatible groups to trap...
This federal Project Grant award from the National Institutes of Health's National Institute on Drug Abuse (CFDA 93.279 - Drug Use and Addiction Research Programs) totaling $1,539,426 provides funding to Serodopa Therapeutics Inc. to develop a novel intranasal formulation of a naloxone derivative as an overdose reversal agent for opioid-induced respiratory depression caused by high-potency opioids like fentanyl. The goals of this Direct-to-Phase II SBIR project are to complete formulation...
This Project Grant award from the National Institute on Drug Abuse, under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $399,536 to Chemregen Inc. to design, synthesize, and test non-opioid drug candidates that could reverse the effects of synthetic opioids like fentanyl. The two-year project aims to characterize the effects of opioids on human induced pluripotent stem cell-derived neurons, with the goal of validating a molecular target and identifying lead compounds...
This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $423,708 to the RU School of Osteopathic Medicine in Stratford, New Jersey to conduct research on fentanyl-xylazine drug mixtures.
The key objectives of this 2-year research project are to: 1) comprehensively characterize the impacts of xylazine on fentanyl-induced changes in cardiorespiratory function and body temperature in rats using...
The U.S. National Institute on Drug Abuse (NIDA) awarded a $9,145,390 Cooperative Agreement under the Drug Use and Addiction Research Programs (CFDA 93.279) to Ensysce Biosciences, Inc. in La Jolla, CA. The goal of this project is to continue the clinical development of PF614-MPAR, an abuse-resistant and overdose-protected opioid product. PF614-MPAR combines the TAAP (Trypsin Activated Abuse Protection) oxycodone prodrug with the trypsin inhibitor nafamostat to provide pain relief at...
The National Institute on Drug Abuse (NIDA) awarded a $244,891 Project Grant (CFDA 93.279 - Drug Use and Addiction Research Programs) to the General Hospital Corporation/Massachusetts General Hospital (MGH) to study the respiratory effects and toxicity of synthetic opioids, like fentanyl, and methamphetamine when co-administered. The research aims to determine the relative contribution of opioid-induced airway compromise and skeletal muscle rigidity to respiratory depression, and how these...
This $1,213,117 project grant awarded by the National Institute on Drug Abuse (CFDA 93.279 - Drug Use and Addiction Research Programs) supports research to develop novel opioid receptor (MOR) agonists and antagonists with improved efficacy and reduced side effects compared to currently available treatments.
The project integrates chemistry, pharmacology, and structural biology to identify and characterize MOR ligands that selectively activate specific G protein signaling pathways, with the...
The National Institute on Drug Abuse (NIDA) awarded a $392,940 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to The University of Texas Health Science Center at San Antonio (UTHSCSA) to conduct research on the "Behavioral Pharmacology of Opioid/Xylazine Mixtures." This research project aims to improve understanding of the interactions between opioids and xylazine, a non-opioid veterinary drug that has become increasingly prevalent as an adulterant in...
This $232,488 Project Grant award from the National Institutes of Health's Trans-NIH Research Support program (CFDA 93.310) is funding research to develop new antidotes that can treat intoxication from a wide range of drugs of abuse, including opioids, stimulants, and hallucinogens. The research aims to systematically optimize the structure of macrocyclic arene compounds to enhance their binding affinity and sequestration capabilities for specific drugs of abuse. The University of Maryland,...